ANRS, Emerging Infectious Diseases: Hepatitis C, Chronic trials

The registry lists 10 Hepatitis C, Chronic studies with ANRS, Emerging Infectious Diseases as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 2 3Phase 3 3No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Cross Sectional Survey on the Burden, Impacts and Causes of Hepatitis C Virus (HCV) Outbreak in South West Region in Burkina FasoStatus unknownNCT04136405
• "Real Life" Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Virus in EgyptStatus unknownNCT03510637
• Evaluation of the National Treatment Program of Hepatitis C in EgyptWithdrawnNCT02101177
• Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis CWithdrawnNCT02099604Phase 3
• Observational Study of B-Cell Non Hodgkin Lymphomas (NHL) Associated With Hepatitis C Virus (HCV)Status unknownNCT01545544
• French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and RibavirinCompletedNCT01514890
• Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin RegimenCompletedNCT01332955Phase 2
• Study Comparing the Tolerability and Viral Reduction of the Combination of IFN a-2b XL + Ribavirin Versus Peg IFN a-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4CompletedNCT01010646Phase 2
• Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.CompletedNCT00323804Phase 2/3
• Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis CCompletedNCT00265642Phase 3